Funders › DE › Uncle Kory Foundation › 2022
Grants paid by Uncle Kory Foundation, tax year 2022
EIN 46-4485313 · El Segundo, DE · Form 990-PF, Part XV · NTEE T99
In tax year 2022, Uncle Kory Foundation (EIN 46-4485313) reported 16 grants paid totaling $800,000. Dataset version 2026.09.0, built 2026-09-03.
Every grant, 2022
| Tax year | Recipient | Match | Amount | Type | Purpose | Source filing |
|---|---|---|---|---|---|---|
| 2022 | The UCLA Foundation Pasadena, CA | C | $150,000 | paid | to conduct preclinical studies of a novel brain-penetrant epidermal growth factor receptor (EGFR) inhibitor and evaluate a noninvasive predictive biomarker of response to the EGFR in malignant GBM, leading to a clinical trial. | 202333169349100213 |
| 2022 | City of Hope Duarte, CA | U | $50,000 | paid | Engineering inhibitors of the ERKS axis proteins for glioblastoma treatment | 202333169349100213 |
| 2022 | The University of Texas Md Anderson Cancer Center Houston, TX | U | $50,000 | paid | Repurposing Migraine Treatments for DIPG - 4th year funding | 202333169349100213 |
| 2022 | The University of Texas Md Anderson Cancer Center Houston, TX | U | $50,000 | paid | Epigenetic Regulation in Pediatric High-Grade Gliomas - 2nd Year Funding | 202333169349100213 |
| 2022 | Society for Neuroscience Los Angeles, CA | C | $50,000 | paid | Characterizing PTPRZ1 Mechanism in Cancer as a Therapeutic Target | 202333169349100213 |
| 2022 | The University of Texas Md Anderson Cancer Center Houston, TX | U | $50,000 | paid | Repurposing Migraine Treatments for DIPG - 3rd year funding | 202333169349100213 |
| 2022 | Cornell University - Weill Cornell Medicine New York, NY | U | $50,000 | paid | for the research project, "Targeting CAFs to sensitize irradiated glioblastoma to PD-1 blockade" | 202333169349100213 |
| 2022 | Mayo Clinic Rochester, MN | U | $50,000 | paid | TARGETING THE MALIGNANT INTERACTION BETWEEN GLIOBLASTOMA AND THE SUBVENTRICULAR ZONE - 2nd year funding | 202333169349100213 |
| 2022 | American Brain Tumor Association Chicago, IL | B | $50,000 | paid | Funding of Discover Grant | 202333169349100213 |
| 2022 | Duke University Durham, NC | B | $50,000 | paid | Research project: Synthetic lethal strategies for targeting ATRX deficiency and the Alternative Lengthening of Telomeres in Pediatric High-Grade Gliomas - 2nd Year Funding | 202333169349100213 |
| 2022 | The Regents of Ucsf San Francisco, CA | U | $50,000 | paid | Developing Multimodal Deep Learning for Outcome Prediction in Glioblastoma Patients After Radiation Therapy | 202333169349100213 |
| 2022 | Johns Hopkins University Baltimore, MD | U | $50,000 | paid | Alpha-particle radiotherapy for glioblastoma | 202333169349100213 |
| 2022 | The UCLA Foundation Pasadena, CA | C | $46,500 | paid | UCLA Brain Cancer Research Gift Fund | 202333169349100213 |
| 2022 | The UCLA Foundation Pasadena, CA | C | $46,500 | paid | Neurosurgery Brain Tumor Program Research Fund | 202333169349100213 |
| 2022 | Central Brain Tumor Registry of the United States Hinsdale, IL | U | $5,000 | paid | General & Unrestricted | 202333169349100213 |
| 2022 | Brain Tumor Epidemiology Consortium Hinsdale, IL | U | $2,000 | paid | To support the 2022 BTEC meeting in Lyon, France; Childhood Brain Tumors: Origins, Epidemiology, and Classification | 202333169349100213 |
Match tier: A Reported EIN · B Exact name and place · C Strong name match · D Probable name match · U Unresolved. Tiers C and D are inferred, not reported; see how matching works.
Recipient matching for this dataset version has not yet completed its independent precision check. Tier A rows carry the EIN the filer reported; tiers B–D are the matcher's inference and should be read as leads until the check is published on the methodology page.
Derived from IRS Form 990-PF e-file XML. Dataset version 2026.09.0, built 2026-09-03. All years for this funder.
The same organization elsewhere in the program: exempt status and filing health · federal awards · grant guidance · open opportunities.
This is informational only, derived from public data on the dates shown. It is not an eligibility determination, and not legal, tax, or accounting advice. Verify against the official source before relying on it.